ARCT (Arcturus Therapeutics Holdings) Total Assets: $245.41 Mil (As of Mar. 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
54 GF Score
Price $6.86
GF Value $4.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Total Assets?

Arcturus Therapeutics Holdings ARCT +0.95% 54 Total Assets is $245.41 Mil as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Arcturus Therapeutics Holdings's Total Assets for the quarter that ended in Mar. 2026 was $245.41 Mil.

During the past 12 months, Arcturus Therapeutics Holdings's average Total Assets Growth Rate was -70.40% per year. During the past 3 years, the average Total Assets Growth Rate was -11.70% per year. During the past 5 years, the average Total Assets Growth Rate was 36.90% per year. During the past 10 years, the average Total Assets Growth Rate was 32.70% per year.

During the past 13 years, Arcturus Therapeutics Holdings's highest 3-Year average Total Assets Growth Rate was 486.70%. The lowest was -29.10%. And the median was 63.20%.

Total Assets is connected with ROA %. Arcturus Therapeutics Holdings's annualized ROA % for the quarter that ended in Mar. 2026 was -41.76%. Total Assets is also linked to Revenue through Asset Turnover. Arcturus Therapeutics Holdings's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Arcturus Therapeutics Holdings  (NAS:ARCT) Total Assets Explanation

Total Assets is connected with ROA %.

Arcturus Therapeutics Holdings's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-107.856/( (271.148+245.411)/ 2 )
=-107.856/258.2795
=-41.76 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Arcturus Therapeutics Holdings's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.61/( (271.148+245.411)/ 2 )
=0.61/258.2795
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Arcturus Therapeutics Holdings Total Assets Related Terms

Arcturus Therapeutics Holdings Total Assets Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings Total Assets Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 392.81 450.39 429.40 344.07 271.15

Arcturus Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 331.79 309.27 282.34 271.15 245.41
ARCT
54GF Score
Arcturus Therapeutics Holdings Inc ARCT
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Arcturus Therapeutics Holdings's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=213.985+57.163
=271.15

Arcturus Therapeutics Holdings's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=191.362+54.049
=245.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $245.41 Mil mean?
Arcturus Therapeutics Holdings (ARCT) has a Total Assets of $245.41 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Arcturus Therapeutics Holdings and its competitors.
Is Arcturus Therapeutics Holdings' Total Assets too high?
Arcturus Therapeutics Holdings' current Total Assets is $245.41 Mil. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Total Assets compare to YDES and RNAC?
Arcturus Therapeutics Holdings' Total Assets of $245.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current Total Assets is $245.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.86 — trading 55.6% above its estimated fair value. The current Total Assets is $245.41 Mil. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Total Assets is $245.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.86 is trading 55.6% above its estimated GF Value™ of $4.41. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Total Assets: $245.41 Mil
  • GF Value™: $4.41 vs. price of $6.86 (55.6% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score

Get the complete analysis for ARCT

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.86
Price
$4.41
GF Value